Immune Biosolutions Inc
Immune Biosolutions is a clinical-stage biotech company based in Quebec, Canada, specializing in the discovery and engineering of avian and human antibodies targeting complex proteins for therapeutic and diagnostic applications. The company focuses on developing immunotherapies for cancer and infectious diseases, leveraging proprietary platforms such as Nebula™ for antibody discovery. It collaborates with international biopharmaceutical companies and academic institutions to advance its programs and has a strong emphasis on innovation in antibody technology, including targeting difficult proteins like GPCRs. The company is actively involved in clinical trials, including those for COVID-19 treatments, and aims to provide solutions that address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Immune Biosolutions Inc
Immune Biosolutions Inc. 2-2650, rue Maximilien-Chagnon Sherbrooke, QC J1E 0M8 Canada
Patents
Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US-10533036-B2
View Details
Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US-10533036-B2
View DetailsProducts
Clinical-stage inhaled antibody therapeutic (inhalation immunotherapy)
A clinical-stage monoclonal antibody cocktail formulated for nebulized inhalation to treat respiratory viral infection; progressed through Phase I/II clinical trials with reported symptom-resolution and viral-load endpoints.
Recombinant antibody candidate portfolios for membrane protein targets
Sets of recombinant monoclonal antibodies generated against GPCRs and other membrane proteins using 3D antigen design, avian immunization and phage-display selection; intended for therapeutic and diagnostic development.
Clinical-stage inhaled antibody therapeutic (inhalation immunotherapy)
A clinical-stage monoclonal antibody cocktail formulated for nebulized inhalation to treat respiratory viral infection; progressed through Phase I/II clinical trials with reported symptom-resolution and viral-load endpoints.
Recombinant antibody candidate portfolios for membrane protein targets
Sets of recombinant monoclonal antibodies generated against GPCRs and other membrane proteins using 3D antigen design, avian immunization and phage-display selection; intended for therapeutic and diagnostic development.
Services
End-to-end antibody discovery using avian immunization, 3D antigen design, phage-display and single B-cell screening, combined with humanization and recombinant engineering; platform access offered to biotech and pharma partners.
GMP-like expression and purification services in an ISO7 cleanroom, including upstream cell culture and bench bioreactor runs, downstream chromatography and TFF, plus analytical testing and release documentation.
Production and purification of high-affinity avian IgY polyclonal antibodies tailored to customer antigens for diagnostic or detection applications.
End-to-end antibody discovery using avian immunization, 3D antigen design, phage-display and single B-cell screening, combined with humanization and recombinant engineering; platform access offered to biotech and pharma partners.
GMP-like expression and purification services in an ISO7 cleanroom, including upstream cell culture and bench bioreactor runs, downstream chromatography and TFF, plus analytical testing and release documentation.
Production and purification of high-affinity avian IgY polyclonal antibodies tailored to customer antigens for diagnostic or detection applications.
Expertise Areas
- Antibody discovery and engineering (avian and humanized antibodies)
- Targeting GPCRs and other membrane proteins
- Recombinant antibody development and humanization
- Biomanufacturing for preclinical and clinical material
Key Technologies
- Avian (IgY) antibody generation
- Antigen design algorithms
- Three-dimensional constrained peptide antigens
- Phage-display selection
News & Updates
Participation in one of the largest life sciences conventions in North America, showcasing innovations and collaborations.
The company announced conclusive results of phase I and II clinical trials demonstrating the efficacy of IBIO123 against COVID-19 variants.
Immune Biosolutions was selected among 22 growing businesses for JLABS @ Toronto, a network of biotech incubators supported by Johnson & Johnson.
Participation in one of the largest life sciences conventions in North America, showcasing innovations and collaborations.
The company announced conclusive results of phase I and II clinical trials demonstrating the efficacy of IBIO123 against COVID-19 variants.
Immune Biosolutions was selected among 22 growing businesses for JLABS @ Toronto, a network of biotech incubators supported by Johnson & Johnson.